|
Crucell Receives US Patent Covering its STAR(TM)
Technology
Leiden, The Netherlands, April 5, 2005 - Dutch biotechnology company Crucell
N.V. (Euronext, NASDAQ: CRXL) announced today that it has been granted a
patent by the United States Patent and Trademark Office for its STAR(TM)
technology.
The newly issued patent is the first and basic patent in a portfolio
pertaining to the STAR(TM) technology developed by professor Arie Otte of
Chromagenics B.V., a company acquired by Crucell in March 2004. The patent
generally covers the identification and selection of so-called STAR(TM)
sequences that find use in boosting the production of therapeutic proteins
in cell-culture systems.
About Crucell
Crucell N.V. is a biotechnology company focused on developing vaccines and
antibodies that prevent and treat infectious diseases, including Ebola,
influenza, malaria, West Nile virus and rabies. The company's development
programs include collaborations with sanofi pasteur for influenza vaccines,
the U.S. National Institutes of Health for Ebola and malaria vaccines, and
GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York
University for a malaria vaccine. Crucell's products are based on its
innovative PER.C6® technology, which offers a safer, more efficient way to
produce biopharmaceuticals. The company licenses its PER.C6® technology to
the biopharmaceutical industry on a mostly non-exclusive basis. Licensees
and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc.
Crucell is headquartered in Leiden, The Netherlands, and is listed on the
Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more
information, please visit www.crucell.com.
This press release contains forward-looking statements
that involve inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially from
those contained in such forward-looking statements. For information relating
to these factors please refer to our Form 20-F, as filed with the U.S.
Securities and Exchange Commission on February 27, 2004, and the section
entitled "Risk Factors". The company prepares its financial statements under
generally accepted accounting principles in the United States (US GAAP).
|
|
